Nicholas Barnes

Professor Barnes is a translational pharmacologist and has been a member of the University of
Birmingham Medical School Faculty since 1990. He is also a founder member of the Neurotrauma Research Group
within the NIHR Surgical Reconstruction and Microbiology Research Centre (SRMRC)) at the Queen Elizabeth
Hospital, Birmingham, one of the largest referral hospitals in Europe. His research
spans from cellular and molecular pharmacological mechanisms to assessing drug efficacy in clinical trial; with
multi-£m funding from for example the MRC, NIHR, the MoD and ‘big and SME’ pharma. He has
generated an extensive list of over 150 research papers and is recognized internationally as one of the World’s most
highly cited researchers. Professor Barnes is Chairman of the International Union of Basic and Clinical Pharmacology
(IUPHAR) Nomenclature Committee for Serotonin Receptors, a Councilor of the International Society for
Serotonin Research and a Fellow of the British Pharmacological Society. He is also Editor-in-Chief for the
international journal Frontiers in Neuropharmacology.

In addition to his academic-related positions, Professor Barnes is the Principal Founder, CEO and Director of
Celentyx Ltd (www.celentyx.com); an originally venture capital financed research and development pharmaceutical
company focusing on treatments for diseases involving the immune system including neuroinflammation and immuno-oncology approaches to treat cancer. The company delivers multi-£m revenue for the UK economy.